MTA is a DNA-binding drug that shows preference for G/C-rich DNA sequences, and, therefore, a significant part of the anti-tumor activity of MTA is thought to be mediated by the blockade of the binding of transcription factors such as Sp1 [21]. This evidence concerns the gene SP1 and neoplasm.